$CPMV
Mosaic ImmunoEngineering Inc.

2024 Q4 Form 10-Q Financial Statement

#000168316824008258 Filed on November 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $39.60K
YoY Change -53.37%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $186.4K
YoY Change -40.22%
Operating Profit -$186.4K
YoY Change -40.22%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$300.00
YoY Change -98.6%
Pretax Income -$186.7K
YoY Change -43.97%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$186.7K
YoY Change -43.97%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03
Diluted Earnings Per Share -$0.03
COMMON SHARES
Basic Shares Outstanding 7.242M shares 7.242M shares
Diluted Shares Outstanding 7.236M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $5.736K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $39.95K
YoY Change -86.01%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $39.95K
Total Long-Term Assets $0.00
Total Assets $39.95K
YoY Change -86.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $143.6K
YoY Change 23.36%
Accrued Expenses $653.7K
YoY Change 0.69%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.301M
YoY Change 16.02%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.301M
Total Long-Term Liabilities
Total Liabilities $6.675M
YoY Change 13.78%
SHAREHOLDERS EQUITY
Retained Earnings -$8.685M
YoY Change 13.97%
Common Stock $72.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.635M
YoY Change
Total Liabilities & Shareholders Equity $39.95K
YoY Change -86.01%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$186.7K
YoY Change -43.97%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
0 usd
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
16 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000836564
dei Document Type
DocumentType
10-Q
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1070278
dei Entity Address Address Line1
EntityAddressAddressLine1
9114 Adams Avenue, #202
dei Entity Address City Or Town
EntityAddressCityOrTown
Huntington Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94646
CY2024Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
34214 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
23355 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
39950 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
179533 usd
CY2024Q3 us-gaap Assets
Assets
39950 usd
CY2023Q4 us-gaap Assets
Assets
179533 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
143618 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
118478 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3641850 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3184911 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
653728 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
641763 usd
us-gaap Net Income Loss
NetIncomeLoss
-712677 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-22182
dei Entity Registrant Name
EntityRegistrantName
MOSAIC IMMUNOENGINEERING, INC.
dei City Area Code
CityAreaCode
657
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7242137 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5736 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
156178 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
787903 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
787903 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
73950 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
0 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5301049 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4733055 usd
CY2024Q3 us-gaap Convertible Debt
ConvertibleDebt
1374031 usd
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
1317536 usd
CY2024Q3 us-gaap Liabilities
Liabilities
6675080 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39599 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
146831 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
186430 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-186430 usd
CY2024Q3 CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
0 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5581029 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6635130 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
usd
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Local Phone Number
LocalPhoneNumber
208-0890
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 us-gaap Liabilities
Liabilities
6050591 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7242137 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7242137 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7242137 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7242137 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
72 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
72 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2050073 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2045206 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8685276 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7916337 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6635130 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5871058 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39950 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
179533 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84927 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
167617 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
385460 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
226944 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
561881 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
738690 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
311871 usd
us-gaap Operating Expenses
OperatingExpenses
729498 usd
us-gaap Operating Expenses
OperatingExpenses
1124150 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-311871 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-729498 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1124150 usd
CY2023Q3 CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
0 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
0 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
433000 usd
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
21000 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
21000 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
4 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
3402 usd
CY2024Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
CY2023Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
46700 usd
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
2817 usd
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
-0 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
3950 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
-0 usd
CY2024Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
18483 usd
CY2023Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
18484 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
55049 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
54849 usd
CY2024Q3 us-gaap Accretion Expense
AccretionExpense
-0 usd
CY2023Q3 us-gaap Accretion Expense
AccretionExpense
2907 usd
us-gaap Accretion Expense
AccretionExpense
1446 usd
us-gaap Accretion Expense
AccretionExpense
14380 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-300 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21375 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39441 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
413873 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-186730 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-333246 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-768939 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-710277 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-186730 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-333246 usd
us-gaap Net Income Loss
NetIncomeLoss
-768939 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7236447 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7236447 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7236447 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7236447 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6448400 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-186730 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6635130 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5253312 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5529 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-333246 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5871058 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4867 usd
us-gaap Net Income Loss
NetIncomeLoss
-768939 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4884758 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16406 usd
us-gaap Net Income Loss
NetIncomeLoss
-712677 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5581029 usd
us-gaap Net Income Loss
NetIncomeLoss
-768939 usd
us-gaap Net Income Loss
NetIncomeLoss
-712677 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4867 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16406 usd
CPMV Gain On Redemption Of Preferred Stock
GainOnRedemptionOfPreferredStock
-0 usd
CPMV Gain On Redemption Of Preferred Stock
GainOnRedemptionOfPreferredStock
433000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
46700 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
55049 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
54849 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
3950 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
us-gaap Accretion Expense
AccretionExpense
1446 usd
us-gaap Accretion Expense
AccretionExpense
14380 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10859 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-8002 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
25140 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-17043 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
456939 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
594661 usd
CPMV Increase Decrease In Accrued Professional Fees
IncreaseDecreaseInAccruedProfessionalFees
0 usd
CPMV Increase Decrease In Accrued Professional Fees
IncreaseDecreaseInAccruedProfessionalFees
55958 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
11965 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
64417 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-220442 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-400747 usd
CPMV Proceeds From Redemption Of Preferred Stock Of Holocom
ProceedsFromRedemptionOfPreferredStockOfHolocom
0 usd
CPMV Proceeds From Redemption Of Preferred Stock Of Holocom
ProceedsFromRedemptionOfPreferredStockOfHolocom
433000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
433000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
70000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-150442 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
32253 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
156178 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
220645 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5736 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252898 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2400 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_807_eus-gaap--NatureOfOperations_zqFhfcIdkfR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>1.        <span id="xdx_82E_zc6pIkA4DvB">Organization and Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Organization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mosaic ImmunoEngineering, Inc. (the “Company,” “Mosaic,” “we,” “us,” or “our”) is a corporation organized under Delaware law on March 24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. We have historically advanced early-stage product candidate and we are pursuing new product candidates and platforms to expand our pipeline based on a deep understanding of immunotherapies and our license agreements with University of California San Diego.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has two inactive wholly owned subsidiaries: Mosaic ImmunoEngineering Development Company, a corporation organized under Delaware law on March 30, 2020 and Patriot Data Solutions Group, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern and Management’s Plans</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. At September 30, 2024, the Company had cash and cash equivalents of $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20240930_zaIYgerAZ6V8" title="Cash and cash equivalents">5,736</span> and has not yet generated any revenues. Therefore, our ability to continue our operations is highly dependent on our ability to raise capital to fund future operations. We anticipate, based on currently proposed plans and assumptions, that our cash and cash equivalents on hand will not satisfy our operational and capital requirements through twelve months from the filing date of this Quarterly Report on Form 10-Q.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are a number of uncertainties associated with our ability to raise additional capital and we have no current arrangements with respect to any additional financing. In addition, the continuation of disruptions caused by COVID-19 or other variants or pandemics, broad-based inflation, and various economic indicators that the United States economy may be entering a recession in upcoming quarters may cause investors to slow down or delay their decision to deploy capital which will adversely impact our ability to fund future operations. Consequently, there can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital will delay our ability to conduct our business operations. Any additional equity financing may involve substantial dilution to our then existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5736 usd
CPMV Aggregate Proceeds From Redemption Of Preferred Stock Of Holocom
AggregateProceedsFromRedemptionOfPreferredStockOfHolocom
433000 usd
CPMV Investment Owned Balance Shares Redeemed
InvestmentOwnedBalanceSharesRedeemed
1242500 shares
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
653728 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
641763 usd
CY2024Q3 CPMV Convertible Notes Redemption Value
ConvertibleNotesRedemptionValue
1145790 usd
CY2024Q3 us-gaap Accretion Expense
AccretionExpense
0 usd
us-gaap Accretion Expense
AccretionExpense
1446 usd
CY2023Q3 us-gaap Accretion Expense
AccretionExpense
2907 usd
us-gaap Accretion Expense
AccretionExpense
14380 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
5529 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4867 usd
us-gaap Share Based Compensation
ShareBasedCompensation
16406 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2024Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.16 pure
CY2024Q2 us-gaap Proceeds From Loans
ProceedsFromLoans
15000 usd
CY2024Q3 us-gaap Proceeds From Loans
ProceedsFromLoans
15000 usd
us-gaap Proceeds From Loans
ProceedsFromLoans
70000 usd
CY2024Q3 us-gaap Other Assets
OtherAssets
7000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
cpmv-20240930_cal.xml Edgar Link unprocessable
cpmv-20240930_pre.xml Edgar Link unprocessable
0001683168-24-008258-index-headers.html Edgar Link pending
0001683168-24-008258-index.html Edgar Link pending
0001683168-24-008258.txt Edgar Link pending
0001683168-24-008258-xbrl.zip Edgar Link pending
cpmv-20240930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mosaic_ex3101.htm Edgar Link pending
mosaic_ex3102.htm Edgar Link pending
mosaic_ex3201.htm Edgar Link pending
mosaic_ex3202.htm Edgar Link pending
mosaic_i10q-093024.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
cpmv-20240930_def.xml Edgar Link unprocessable
cpmv-20240930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mosaic_i10q-093024_htm.xml Edgar Link completed
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending